Takeda oncology vet drills down the ‘basics’ at cell therapy startup; Sarepta promotes new R&D chief

Kathryn Corzo

Kathryn Corzo — an oncology veteran and the program head behind Sanofi’s multiple myeloma monoclonal antibody isatuximab — is now in the C-suite.

The newest member at cell therapy player bit.bio as their COO, the longtime drug developer left Takeda...

Click to view original post